Clinical and Molecular Significance of Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Breast Cancer of African Women and its Potential as a Targeted Therapy

Background: The therapeutic effects of Poly (ADP-ribose) polymerase-1 (PARP -1) inhibition are currently studied in a clinical trial that is recruiting African- American (A-A) women with breast cancer (BC). Although, A-A and West African women are likely to share the same ancestry, there are overwhelming evidences, that BC is undoubtedly heterogeneous which might influence results obtained in these Nationalities. Thus, this study aims to investigate PARP-1 expression in a large and annotated series of breast cancer from Nigerian women to determine its clinical and biological significance for the indigenous African women. Methods: PARP-1 protein expression was assessed immunohistochemically in 204 formalin fixed paraffin samples from Nigerian breast cancer women prepared as TMA. Results: PARP-1 was inversely associated with steroid hormone receptors (oestrogen (ER) and progesterone (PR) receptor), the Homologous Recombination marker BRCA1 associated ring domain 1 (BARD1) and p27. Conversely, a positive association was established between PARP-1 and high histologic grade, expression of basal markers (cytokeratins (CK) 5/6 and 14) and epidermal growth factor receptor (EGFR)), DNA damage-repair markers (protein inhibitor of activator signal transducer gamma (PIAS)), the BRCA1 inhibitor (metastasis tumour antigen-1 (MTA1), p53, the proliferation markers (KI-67, Phosphoinositide-3-kinases (PI3KCA)), the triple-negative and basal-like phenotypes. Outcome analysis indicated PARP-1 as a predictor of poor survival independent of tumour size, histological grade and lymph node involvement. Conclusion: These results provide evidence that PARP-1 plays an important role in Nigerian women with breast cancer. It is recommended that indigenous Black women from Africa are included in the ongoing clinical trial of PARP1 inhibitors that is aimed at determining the efficiency of the drug in black BC women outside United States.

[1]  I. Ellis,et al.  Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women , 2013, ISRN oncology.

[2]  I. Ellis,et al.  Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women , 2012, Breast Cancer Research and Treatment.

[3]  V. Schreiber,et al.  The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. , 2012, Biochemical pharmacology.

[4]  W. Kraus,et al.  On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. , 2012, Genes & development.

[5]  J.,et al.  The New England Journal of Medicine , 2012 .

[6]  J. Lubiński,et al.  PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy , 2011, Breast Cancer Research and Treatment.

[7]  Ning Wu,et al.  Increased levels of p53 and PARP-1 in EL-4 cells probably related with the immune adaptive response induced by low dose ionizing radiation in vitro. , 2010, Biomedical and environmental sciences : BES.

[8]  S. Bhide,et al.  Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. , 2010, Cancer treatment reviews.

[9]  R. Bristow,et al.  Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. , 2010, Seminars in radiation oncology.

[10]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[11]  S. Gygi,et al.  PIASy Mediates SUMO-2/3 Conjugation of Poly(ADP-ribose) Polymerase 1 (PARP1) on Mitotic Chromosomes* , 2010, The Journal of Biological Chemistry.

[12]  I. Ellis,et al.  Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens , 2010, Histopathology.

[13]  Melanie Keppler,et al.  The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress , 2009, Nature.

[14]  S. Jackson,et al.  Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote responses to DNA double-strand breaks , 2009, Nature.

[15]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[16]  S. Izraeli,et al.  A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors , 2009, Breast Cancer Research.

[17]  R. Tuma.  PARP inhibitors: will the new class of drugs match the hype? , 2009, Journal of the National Cancer Institute.

[18]  Z. Lengyel,et al.  RETRACTED ARTICLE: Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Expression in Cutaneous Malignant Melanomas as a New Molecular Marker of Aggressive Tumor , 2009, Pathology & Oncology Research.

[19]  W. Kraus.  Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. , 2008, Current opinion in cell biology.

[20]  M. Yaffe,et al.  MDC1 Directly Binds Phosphorylated Histone H2AX to Regulate Cellular Responses to DNA Double-Strand Breaks , 2008, Cell.

[21]  W. Figg,et al.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 , 2008, Molecular Cancer Therapeutics.

[22]  Alice S Whittemore,et al.  Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. , 2007, JAMA.

[23]  Zhao-Qi Wang,et al.  Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients. , 2007, Mutation research.

[24]  Kathleen Marchal,et al.  The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. , 2007, Cancer research.

[25]  Zhao-Qi Wang,et al.  Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice , 2007, Oncogene.

[26]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[27]  Phil Quirke,et al.  Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer , 2006, Clinical Cancer Research.

[28]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Y. Kim,et al.  Poly(ADP-ribosyl)ation by PARP-1: 'PAR-laying' NAD+ into a nuclear signal. , 2005, Genes & development.

[30]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[31]  C. Rotimi,et al.  Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients , 2005, Journal of Medical Genetics.

[32]  G. de Murcia,et al.  PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis. , 2005, The Biochemical journal.

[33]  P. Johnston,et al.  The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.

[34]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[35]  Robert Almassy,et al.  Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. , 2004, Journal of the National Cancer Institute.

[36]  O. Olopade,et al.  Breast cancer genetics in African Americans , 2003, Cancer.

[37]  O. Olopade,et al.  Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer , 2001, Human Genetics.

[38]  H. Stürzbecher,et al.  Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer , 2000, International journal of cancer.

[39]  Thomas Ried,et al.  DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation , 2000, Nature.

[40]  G. Poirier,et al.  Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.

[41]  M. Spitz,et al.  Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. , 1999, Carcinogenesis.

[42]  V. Chen,et al.  Racial disparity in the association of p53 gene alterations with breast cancer survival. , 1995, Cancer research.

[43]  T. Lindahl.  Instability and decay of the primary structure of DNA , 1993, Nature.